08-29-02

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket N (Under 37 CFR 1.97(b) or 1.97(c)) **UAB-1540** In Re Application Of: Jay M. Meythaler et al. Serial No. Filing Date Examiner Group Art Unit 10/049,328 02/11/2002 Title: USE OF GABA AGONISTS FOR TREATMENT OF SPASTIC DISORDERS, CONVULSION AND EPILEPSY Address to: **Assistant Commissioner for Patents** Washington, D.C. 20231 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2.

The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR \Box the fee set forth in 37 CFR 1.17(p).

EV15384/2883US

	7(c))	Docket No. UAB-15402/22			
In Re Application: Ja	ay M. Meythaler et al.				
Serial No. 10/049,328	Filing Date 02/11/2002	Examiner	Group Art Unit		
PUSE OR GABA AC	GONISTS FOR TREATMENT O	DF SPASTIC DISORDERS, CONVU	LSIONS, AND		
AUG 2 8 2002 2			REC!		
☐ Charge th ☐ Credit any ☑ Charge ar ☐ Certificate of T ☐ I certify that this docume account is being facsin Patent and Trademark C ☐ (Date) ☐ Typed or Printed No.	e amount of v overpayment. ny additional fee required. ransmission by Facsimile* ent and authorization to charge deposite the transmitted to the United States	Certificate of Mailing by	EXPRESS First Class Mail ee is being deposited e U.S. Postal Service C.F.R. 1.8 and is missioner for Patents, 2389588345 Ling Correspondence		
weny /	gnature nkle, 2.C, Ste. 400	Dated: Sugast 25	7 20a		

				Docket Number (Optional) UAB-15402		Application Number 10/049,328							
					Applicant(s) Jay Meythaler et al.								
	(Use several sheets if necessary)				Filing Date	I	Group Art Unit						
					02/11/2002								
				U.S. PAT	ENT DOCUMENTS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
(\$	E	5,474,547	12/12/95	Aebischer et al.		604	891.1	· 					
0	<u> </u>	5,832,932	11/10/98	Elsberry et al.		128	898						
AUG	282	OFFIGE STATES											
CATENT	& TRA	EMPE					7						
						16		T)					
							THE SELVE OF THE S	N	<u> </u>				
							100	(2)					
							1	3					
				FOREIG	N PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DOCUMENT NUMBER DATE		COUNTRY CL.		SUBCLASS	Translation YES NO					
					-								
	<u> </u>												
,						···							
									·				
						Author, Title, I	Date, Pertinent Pa	ges, Etc.)					
		Hsu, C.Y. et al., "Cell											
		Juurlink, B. et al., "R Nutritional Managem	Juurlink, B. et al., "Review of Oxidative Stress in Brain and Spinal Cord Injury: Suggestions for Pharmacological and Nutritional Management Strategies," The Journal of Spinal Cord Medicine, 21:309-334;1998.										
		Smith, D. H. et al., "T	Smith, D. H. et al., "Traumatic Brain Injury and Excitatory Amino Acids," 107:1445-1458.										
EXAMINE	R				DATE CONSIDERED		<u>-</u>	-					
EXAMINE	R: Initi	al if citation considered, whethe	er or not citation is i	n conforman	ce with MPEP Section 609;	Draw line thro	igh citation if not	in conform	ance and				

Form PTO-A820 (also form PTO-1449)

not considered. Include copy of this form with next communication to applicant.

P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE